@JournalofNucMed publishes new consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy for the management of management of mCRPC. #ReadNow details on UroToday > https://t.co/SMSl6oix6J @SNM_MI
Interesting discussion in @EUplatinum about control arm/design of VISION trial
Ultimately, while Lu-PSMA is highly active (⬆️ PSA RR, PFS, QoL), results from TheraP (not powered for OS) bring into question if it actually ⬆️ OS against "optimal" SOC in 3L mCR #prostatecancer